173 related articles for article (PubMed ID: 25942998)
21. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process.
Neumann PJ
Med Care; 2005 Jul; 43(7 Suppl):27-32. PubMed ID: 16056006
[TBL] [Abstract][Full Text] [Related]
22. Communication about results of comparative effectiveness studies: a pharmaceutical industry view.
Perfetto EM; Bailey JE; Gans-Brangs KR; Romano SJ; Rosenthal NR; Willke RJ
Health Aff (Millwood); 2012 Oct; 31(10):2213-9. PubMed ID: 23048099
[TBL] [Abstract][Full Text] [Related]
23. Weighing the evidence: trends in managed care formulary decision making.
de Lissovoy G
J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
[TBL] [Abstract][Full Text] [Related]
24. Communicating Healthcare Economic and Pre-approval Information With Healthcare Decision-Makers: Opportunities Following the 21st Century Cures Act and FDA Guidance.
Niyazov A; Lenci D
Front Public Health; 2018; 6():304. PubMed ID: 30488029
[TBL] [Abstract][Full Text] [Related]
25. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
26. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
[TBL] [Abstract][Full Text] [Related]
27. Pharmacy benefit management companies (PBMs). Why should we be interested?
Shulman SR
Pharmacoeconomics; 1998; 14 Suppl 1():49-56. PubMed ID: 10186482
[TBL] [Abstract][Full Text] [Related]
28. The US Food and drug administration: drug information resource for formulary recommendations.
Marchand HC; Ros BJ; Fine AM; Kremzner ME
J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
[TBL] [Abstract][Full Text] [Related]
29. What patients think about promotional activities of pharmaceutical companies in Turkey.
Semin S; Güldal D; Ozçakar N; Mevsim V
Pharm World Sci; 2006 Aug; 28(4):199-206. PubMed ID: 17066242
[TBL] [Abstract][Full Text] [Related]
30. AMCP Partnership Forum: Biosimilars--Ready, Set, Launch.
J Manag Care Spec Pharm; 2016 Apr; 22(4):434-40. PubMed ID: 27023697
[TBL] [Abstract][Full Text] [Related]
31. The potential for self-interested behavior by pharmaceutical manufacturers through vertical integration with pharmacy benefit managers: the need for a new regulatory approach.
Mitchell EL
Food Drug Law J; 1999; 54(1):151-83. PubMed ID: 11758556
[No Abstract] [Full Text] [Related]
32. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
33. The expanding role of pharmacists. Interview by Patrick Mullen.
Cahill J
Manag Care; 2001 Aug; 10(8):49-52, 57. PubMed ID: 11565384
[No Abstract] [Full Text] [Related]
34. Food labeling: health claims; vitamin K and promotion of proper blood clotting and improvements in bone health in adults--FDA. Interim final rule.
Fed Regist; 1998 Jun; 63(119):34115-7. PubMed ID: 10180292
[TBL] [Abstract][Full Text] [Related]
35. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
[TBL] [Abstract][Full Text] [Related]
36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
37. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
Watkins JB; Minshall ME; Sullivan SD
J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
[TBL] [Abstract][Full Text] [Related]
38. A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics.
Neumann PJ; Saret CJ
Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):657-61. PubMed ID: 24138650
[TBL] [Abstract][Full Text] [Related]
39. Focus group on pharmacy and managed care.
Am J Health Syst Pharm; 1997 Nov; 54(21):2500-2. PubMed ID: 9359958
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the Presence of Cognitive Biases in Health Care Decision Making: A Survey of U.S. Formulary Decision Makers.
Mezzio DJ; Nguyen VB; Kiselica A; O'Day K
J Manag Care Spec Pharm; 2018 Nov; 24(11):1173-1183. PubMed ID: 30362919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
